Depression can be an almost intolerable burden to live with. While antidepressants help many to soothe their symptoms, many others find no relief in these substances. A decades-old drug, ketamine, is now offering hope to many of these people. Ketamine was first discovered in 1962.
"We're particularly interested in training students to enter the growth pharmaceutical industry surrounding the use of these substances, providing them with the tools to understand the data and also to work in an ethical manner and adhere to all the regulatory pieces surrounding the use of these compounds," he said.
Canada-based Algernon announced its clinical program in January based in part on a preclinical study published last year in Experimental Neurology by researchers from Semmelweis University, which showed DMT can promote neurogenesis and neuroplasticity in a rat model of brain ischemia.
Psilocybin may have therapeutic value for many common neuropsychiatric disorders, including depression, obsessive-compulsive disorder, and substance use disorder.
Psygen is a Calgary-based company specializing in the synthetic manufacture of psychedelic medicines. The company provides non-exclusive access to psychedelic drug products for clinical research, therapeutic applications and is a leading supplier for the emerging commercial market.
How likely is the FDA to approve MDMA to treat PTSD? It is, after all, a psychedelic drug in Schedule I, which defines it as highly dangerous with no therapeutic value. Apparently, back in 2017, the FDA identified MDMA as a ‘breakthrough therapy’ for PTSD.
Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director
